Aug 2026· Epigenomes· Vol 10, pp. 54· 0 citations· 56 references
Medicine
TL;DR
The observed decline in MRSCRP following ART initiation may reflect changes in inflammatory status among PWH, and highlights the potential of MRSCRP as a marker of inflammation-related changes and comorbidity risk in PWH.
Abstract
Background/Objectives: Human immunodeficiency virus (HIV) infection is characterized by chronic systemic inflammation. Antiretroviral therapy (ART) can reduce persistent inflammation, as measured by C-reactive protein (CRP). The CRP methylation risk score (MRSCRP) acts as proxy for plasma CRP, but longitudinal changes in this score for people with HIV (PWH) before and after initiating ART have not been described. Methods: We evaluated a previously published MRSCRP in the Emory Twin Study (N = 352), testing its correlation with plasma CRP and CRP-responsive biomarkers, as well as associations with cardiometabolic traits using generalized estimating equations (GEEs). We then applied MRSCRP in the HIV AIDS Drug Resistance Surveillance Study (ADReSS) cohort (N = 440) to assess longitudinal changes before and after ART, using paired t-tests and linear mixed-effects models. Results: MRSCRP showed moderate correlation with CRP (r = 0.38) and other inflammatory biomarkers (r = 0.25–0.34). MRSCRP was associated with hypertension, type 2 diabetes, coronary artery disease, and obesity, and remained independently associated with obesity (odds ratio = 1.49) after adjusting for measured CRP. Z-score-standardized MRSCRP decreased by 0.254 standard deviation units between baseline and follow-up among PWH receiving ART, confirmed by linear mixed-effects models. Conclusions: MRSCRP showed associations with chronic inflammation and cardiometabolic diseases. The observed decline in MRSCRP following ART initiation may reflect changes in inflammatory status among PWH. These findings highlight the potential of MRSCRP as a marker of inflammation-related changes and comorbidity risk in PWH.
Metabolic syndrome (MS) is highly prevalent among people living with HIV (PLWH) receiving antiretroviral therapy (ART) and is driven by persistent low-grade inflammation. Hypoxia-inducible factor 1 alpha (HIF-1α) polymorphisms may influence inflammatory pathways underlying MS. This study investigated the association of...
Nemanja Đorđević, J. Ranin, I. Gmizić et al.· PLoS ONE· 0 citations
Traditional risk factors for atherosclerotic cardiovascular disease (ASCVD) fail to fully reflect the residual risk, driven by chronic low-grade inflammation, observed in many. Generally, high-sensitivity C-reactive protein (hsCRP) concentrations remain stable, but some individuals may experience increases. More...
F. Kahles, M. Reugels, K. Schneider et al.· European Heart Journal· 0 citations
Background Large-scale studies have demonstrated a temporal relationship between insulin resistance (IR) and peripheral inflammation, with emerging evidence also suggesting a link to cognitive decline. However, most of the existing research has focused on individual inflammatory proteins, while the role of inflammatory...
C. Schiweck, Judith R. Gruber, J. Bralten et al.· Brain, Behavior, & Immunity...· 0 citations
Systemic inflammation is a key driver of cardiovascular risk in metabolic syndrome (MetS). Although C-reactive protein (CRP) is widely used, its prognostic value may be enhanced by cellular immune markers such as the neutrophil-to-lymphocyte ratio (NLR), which integrates innate and adaptive inflammatory pathways....
J. Yang, M. Li, Z. Zhang et al.· European Heart Journal· 0 citations
Abstract Introduction The C-reactive protein–triglyceride-glucose index (CTI) has emerged as an innovative biomarker for insulin resistance and inflammatory processes. Nevertheless, the association between CTI and diabetic vascular complications (DVCs) and its subtypes in individuals with diabetes remains unclear. Meth...
Shi-Kai Xiong, Hao Wang, Bin Wang et al.· BMJ public health· 0 citations
High-sensitivity C-reactive protein (hsCRP) is the guideline-recommended biomarker for assessment of residual inflammatory risk in atherosclerotic cardiovascular disease (ASCVD). Clinical adoption remains limited, especially in individuals without established ASCVD. This study used longitudinal measurements to ev...
B. Kurt, M. Reugels, K. Schneider et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.